Exact Sciences Corporation
EXAS
Classificação em ações
#1155
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Preço da ação
$104.91
Última sincronização: 2026-03-23
Valor de mercado
$20.03B
Variação (1 dia)
0.00%
Variação (1 ano)
65.45%
País
US
Negociar Exact Sciences Corporation (EXAS)
Categoria
Healthcare
Receita da Exact Sciences Corporation (EXAS)
Receita em Dec 2025 TTM: $3.25B
De acordo com os últimos relatórios financeiros da Exact Sciences Corporation, a receita atual da empresa (TTM) é $3.25B. Em 2024, a empresa obteve uma receita de $2.76B um aumento em relação a a receita do ano 2023, que foi de $2.50B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Exact Sciences Corporation de 2000 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $3.25B | 0.00% |
| 2025 | $3.25B | 17.69% |
| 2024 | $2.76B | 10.37% |
| 2023 | $2.50B | 19.93% |
| 2022 | $2.08B | 17.95% |
| 2021 | $1.77B | 18.49% |
| 2020 | $1.49B | 70.19% |
| 2019 | $876.29M | 92.82% |
| 2018 | $454.46M | 70.86% |
| 2017 | $265.99M | 167.66% |
| 2016 | $99.38M | 151.99% |
| 2015 | $39.44M | 2,093.38% |
| 2014 | $1.80M | -56.61% |
| 2013 | $4.14M | 0.00% |
| 2012 | $4.14M | -0.46% |
| 2011 | $4.16M | -22.10% |
| 2010 | $5.34M | 12.32% |
| 2009 | $4.76M | -648.79% |
| 2008 | $-867.00K | -129.54% |
| 2007 | $2.94M | -38.21% |
| 2006 | $4.75M | 11.76% |
| 2005 | $4.25M | -13.88% |
| 2004 | $4.94M | 70.11% |
| 2003 | $2.90M | 223.41% |
| 2002 | $897.00K | 1,663.32% |
| 2001 | $50.87K | 0.00% |
| 2000 | 0.00 | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $46.34B | 1,327.04% |
US
|
|
| $25.11B | 673.24% |
US
|
|
| $2.71B | -16.63% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 127.04% |
US
|
